Clinical TrialsRoche advances Elevidys with planned Phase III study to support EMA resubmi... Roche advances Elevidys with planned Phase III study to support EMA resubmi... Read Post »
Health Tidings Mergers & AcquisitionsVir Biotechnology Closes Astellas Deal to Advance VIR-5500 in Prostate Canc... Vir Biotechnology Closes Astellas Deal to Advance VIR-5500 in Prostate Canc... Read Post »
New Drug ApprovalEC Approves ENFLONSIA for RSV Prevention in Infants Across Europe EC Approves ENFLONSIA for RSV Prevention in Infants Across Europe Read Post »
Mergers & AcquisitionsAligos and Amoytop Enter Strategic Licensing Pact for HBV Therapy in Greate... Aligos and Amoytop Enter Strategic Licensing Pact for HBV Therapy in Greate... Read Post »
New Drug ApprovalNICE Backs Belantamab Mafodotin for Relapsed Multiple Myeloma in NHS NICE Backs Belantamab Mafodotin for Relapsed Multiple Myeloma in NHS Read Post »
Clinical TrialsLilly Bolsters Foundayo’s Case with ACHIEVE-4 Data Under FDA Scrutiny Lilly Bolsters Foundayo’s Case with ACHIEVE-4 Data Under FDA Scrutiny Read Post »
Regulatory & Health PolicyFDA Lays the Groundwork for Expanding Testosterone Therapy’s Reach FDA Lays the Groundwork for Expanding Testosterone Therapy’s Reach Read Post »
Mergers & AcquisitionsMeiraGTx Takes the Lead on Bota-vec, Driving Toward Regulatory Approval in ... MeiraGTx Takes the Lead on Bota-vec, Driving Toward Regulatory Approval in ... Read Post »
Clinical TrialsTurning the Tap Back On: MeiraGTx’s AAV-hAQP1 Delivers Three-Year Durabil... Turning the Tap Back On: MeiraGTx’s AAV-hAQP1 Delivers Three-Year Durabil... Read Post »
Clinical TrialsBayer Advances a Safer Clot Strategy as Asundexian Lowers Stroke Risk by 26... Bayer Advances a Safer Clot Strategy as Asundexian Lowers Stroke Risk by 26... Read Post »
Health TidingsMolgramostim Review Timeline Extended, FDA Seeks More Time on Savara’s BL... Molgramostim Review Timeline Extended, FDA Seeks More Time on Savara’s BL... Read Post »
Clinical TrialsAicuris Advances Pritelivir with Priority Review and Strong Phase 3 Data Aicuris Advances Pritelivir with Priority Review and Strong Phase 3 Data Read Post »
New Drug ApprovalFDA Clears Expanded Use of Caldolor for Postoperative Pain Treatment FDA Clears Expanded Use of Caldolor for Postoperative Pain Treatment Read Post »
Health TidingsFDA to Puts Peptides Back Under Scientific Review FDA to Puts Peptides Back Under Scientific Review Read Post »
Health TidingsImmutep Win Orphan Drug Designation for Eftilagimod Alfa in STC Immutep Win Orphan Drug Designation for Eftilagimod Alfa in STC Read Post »
Drugs Safety AlertFDA Requires Extensive Postmarketing Safety Data for Foundayo FDA Requires Extensive Postmarketing Safety Data for Foundayo Read Post »
Health TidingsBIZENGRI Steps into the Breach: A Targeted Push Against Rare Bile Duct Canc... BIZENGRI Steps into the Breach: A Targeted Push Against Rare Bile Duct Canc... Read Post »
Health TidingsArbutus Moves Imdusiran Forward Under FDA Fast Track for HBV Arbutus Moves Imdusiran Forward Under FDA Fast Track for HBV Read Post »
Health TidingsLEO Pharma Breaks New Ground as ANZUPGO Moves Toward Pediatric Approval for... LEO Pharma Breaks New Ground as ANZUPGO Moves Toward Pediatric Approval for... Read Post »
Regulatory & Health PolicySandoz Plants a Strategic Supply Anchor in Africa with Rwanda Manufacturing... Sandoz Plants a Strategic Supply Anchor in Africa with Rwanda Manufacturing... Read Post »
Clinical TrialsAstellas Ignites a New Front in KRAS G12D Battle with Phase 3 Entry of Seti... Astellas Ignites a New Front in KRAS G12D Battle with Phase 3 Entry of Seti... Read Post »
Health Tidings Mergers & AcquisitionsIllumina and D3b Construct a Unified Genomic Core to Break Pediatric Data S... Illumina and D3b Construct a Unified Genomic Core to Break Pediatric Data S... Read Post »
Mergers & AcquisitionsBoehringer and Zai Lab Sharpen a Two-Edge Strategy to Cut Through DLL3 Tumo... Boehringer and Zai Lab Sharpen a Two-Edge Strategy to Cut Through DLL3 Tumo... Read Post »
Clinical TrialsINGREZZA Secures the Long Game as AUSTEDO XR Lags in Treatment Persistence INGREZZA Secures the Long Game as AUSTEDO XR Lags in Treatment Persistence Read Post »
Mergers & AcquisitionsMesoblast Expands Its Cell Therapy Territory with CAR-Powered Precision Pla... Mesoblast Expands Its Cell Therapy Territory with CAR-Powered Precision Pla... Read Post »
Mergers & AcquisitionsGSK’s Bold Lungstrike: Acquiring 35Pharma to Unleash HS235 on PH GSK’s Bold Lungstrike: Acquiring 35Pharma to Unleash HS235 on PH Read Post »
Clinical TrialsAligos Maps a Wider HBV Horizon as Pevifoscorvir Gains Ground in Phase 2 Aligos Maps a Wider HBV Horizon as Pevifoscorvir Gains Ground in Phase 2 Read Post »
GenericsOrbicular–Apotex–Gland Seal the First-Market Vault with CGT Exclusivity... Orbicular–Apotex–Gland Seal the First-Market Vault with CGT Exclusivity... Read Post »
Health TidingsPartnership Capital Fuels Lenacapavir’s Surge into the HIV Prevention Fro... Partnership Capital Fuels Lenacapavir’s Surge into the HIV Prevention Fro... Read Post »
Clinical TrialsDaraxonrasib Ignites a Survival Breakthrough in Pancreatic Cancer’s Tough... Daraxonrasib Ignites a Survival Breakthrough in Pancreatic Cancer’s Tough... Read Post »
Regulatory & Health PolicyFDA Sets the Coordinates for Safe Navigation in Genome Editing FDA Sets the Coordinates for Safe Navigation in Genome Editing Read Post »
Clinical TrialsSpyre’s SPY001 Pushes the Boundary of UC Care with Promising Induction Re... Spyre’s SPY001 Pushes the Boundary of UC Care with Promising Induction Re... Read Post »
Mergers & AcquisitionsAbbVie Builds Pain Portfolio Through Broad Licensing Pact With Haisco AbbVie Builds Pain Portfolio Through Broad Licensing Pact With Haisco Read Post »
Health TidingsDARZALEX Powers Past Expectations with $3.96 Billion Q1 Sales Surge DARZALEX Powers Past Expectations with $3.96 Billion Q1 Sales Surge Read Post »
Health TidingsPraxis Enters FDA Review Arena With Ulixacaltamide for Essential Tremor Praxis Enters FDA Review Arena With Ulixacaltamide for Essential Tremor Read Post »
Mergers & AcquisitionsNovo Nordisk Taps OpenAI to Supercharge the Drug Discovery Engine Novo Nordisk Taps OpenAI to Supercharge the Drug Discovery Engine Read Post »
Clinical TrialsIDEAYA and Servier Anchor Darovasertib Combo in Metastatic Uveal Melanoma IDEAYA and Servier Anchor Darovasertib Combo in Metastatic Uveal Melanoma Read Post »
Clinical TrialsEmactuzumab Breaks the Cycle of Chronic Therapy in TGCT with Phase 3 Result... Emactuzumab Breaks the Cycle of Chronic Therapy in TGCT with Phase 3 Result... Read Post »
Health TidingsBioVersys and GSK’s AlpE Rewires Drug-Resistant Tuberculosis in Preclinic... BioVersys and GSK’s AlpE Rewires Drug-Resistant Tuberculosis in Preclinic... Read Post »
Clinical TrialsAllogene Brings CAR T to the Frontline Edge, ALPHA3 Shows Early MRD Win Allogene Brings CAR T to the Frontline Edge, ALPHA3 Shows Early MRD Win Read Post »
Health TidingsFDA Shines a Floodlight on Hidden Trial Data, Urges Sponsors to Report Miss... FDA Shines a Floodlight on Hidden Trial Data, Urges Sponsors to Report Miss... Read Post »
New Drug ApprovalFILSPARI Unlocks the Door for FSGS With First FDA Approval FILSPARI Unlocks the Door for FSGS With First FDA Approval Read Post »
Mergers & AcquisitionsRegeneron and Telix Set 50/50 Course for Targeted Radiopharma Expansion Regeneron and Telix Set 50/50 Course for Targeted Radiopharma Expansion Read Post »
Clinical TrialsOcular Therapeutix Shows Durable Wet AMD Control With AXPAXLI Ocular Therapeutix Shows Durable Wet AMD Control With AXPAXLI Read Post »
Health TidingsPriority Review Signals Momentum for Ifinatamab Deruxtecan in ES-SCLC Priority Review Signals Momentum for Ifinatamab Deruxtecan in ES-SCLC Read Post »
Health TidingsGenmab Advances Rina-S Combination After Clean Safety Readout Genmab Advances Rina-S Combination After Clean Safety Readout Read Post »
Health TidingsJaypirca Triple Combo Delays Relapse in Phase 3 CLL Trial Jaypirca Triple Combo Delays Relapse in Phase 3 CLL Trial Read Post »
New Drug ApprovalDupixent Extends Its Reach to Young CSU Patients in EU Dupixent Extends Its Reach to Young CSU Patients in EU Read Post »
Health TidingsRoche’s Vabysmo Breaks the Six-Month Ceiling in RVO Care Roche’s Vabysmo Breaks the Six-Month Ceiling in RVO Care Read Post »
Clinical TrialsAbbVie’s ELAHERE Combo Drives a Targeted Assault on FRα-Positive Tumors AbbVie’s ELAHERE Combo Drives a Targeted Assault on FRα-Positive Tumors Read Post »
